PYRIDOSTIGMINE BROMIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Pyridostigmine Bromide, and when can generic versions of Pyridostigmine Bromide launch?
Pyridostigmine Bromide is a drug marketed by Amneal, Milla Pharms, MSN, Novitium Pharma, Rising, Alvogen, Impax Labs Inc, Ani Pharms, Impax Labs, MLV, Solvay, Us Army, and Zydus Pharms. and is included in fifteen NDAs.
The generic ingredient in PYRIDOSTIGMINE BROMIDE is pyridostigmine bromide. There are eleven drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the pyridostigmine bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pyridostigmine Bromide
A generic version of PYRIDOSTIGMINE BROMIDE was approved as pyridostigmine bromide by IMPAX LABS on April 24th, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PYRIDOSTIGMINE BROMIDE?
- What are the global sales for PYRIDOSTIGMINE BROMIDE?
- What is Average Wholesale Price for PYRIDOSTIGMINE BROMIDE?
Summary for PYRIDOSTIGMINE BROMIDE
US Patents: | 0 |
Applicants: | 13 |
NDAs: | 15 |
Finished Product Suppliers / Packagers: | 20 |
Raw Ingredient (Bulk) Api Vendors: | 117 |
Clinical Trials: | 21 |
Patent Applications: | 1,216 |
What excipients (inactive ingredients) are in PYRIDOSTIGMINE BROMIDE? | PYRIDOSTIGMINE BROMIDE excipients list |
DailyMed Link: | PYRIDOSTIGMINE BROMIDE at DailyMed |
Recent Clinical Trials for PYRIDOSTIGMINE BROMIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Vermont Medical Center | Phase 2 |
Stefan Holubar MD MS FACS, FASCRS | Phase 2/Phase 3 |
Michael Debakey Veterans Affairs Medical Center | Early Phase 1 |
Pharmacology for PYRIDOSTIGMINE BROMIDE
Drug Class | Cholinesterase Inhibitor |
Mechanism of Action | Cholinesterase Inhibitors |